RECOVERY trial closed recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
On Jan. 15, 2021, Oxford University announced that on advice of the independent Data Monitoring Committee (DMC), recruitment…
VBI Vaccines announced publication of results from phase 4 study of prophylactic 3-ntigen HBV in vaccine
On Jan. 15, 2021, VBI Vaccines announced that results from a Phase 4 study of VBIﾒs prophylactic 3-antigen…
Pfizer and BioNTech announced European scale-up of manufacturing capacities
On Jan. 15, 2021, Pfizer and BioNTech announced they had developed a plan that allowed the scale-up of…
UW researchers develop tool to equitably distribute limited vaccines
On Jan. 15, 2021, researchers at the University of Wisconsin School of Medicine and Public Health and UW…
PerkinElmer SARS-CoV-2 RT-PCR assay received FDA EUA for asymptomatic testing
On Jan. 14, 2021, PerkinElmer announced that its PerkinElmerﾮ Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization…
COVID-19 reduced US life expectancy, especially among Black and Latino populations
On Jan. 14, 2021, USC and Princeton researchers reported that the COVID-19 pandemic, which claimed more than 336,000…
Cepheid received Health Canada license for SARS-CoV-2, Flu A, Flu B and RSV combination test
On Jan. 14, 2021, Cepheid that Health Canada announced that it had issued Cepheid a medical device license…
Twist Bioscience began shipping of synthetic RNA controls for UK variant strain of SARS-CoV-2
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
Innovation Pharma’s Brilacidin for the treatment of COVID-19 received FDA Fast Track Designation
On Jan. 14, 2021, Innovation Pharmaceuticals announced that the FDA had designated as a Fast Track development program…
Alexion updated phase 3 study of ULTOMIRISﾮ (ravulizumab-cwvz) in hospitalized patients with COVID-19
On Jan. 13, 2021, Alexion announced the decision to pause further enrollment in the global Phase 3 study…
Oxford Immunotec’s T-SPOT SARS-CoV-2 test used to measure efficacy of Valneva’s COVID-19 vaccine candidate
On Jan. 13, 2021, Oxford Immunotec announced the start of a collaboration with Valneva whereby it will perform…
The USDA confirmed COVID-19 in gorillas at San Diego Zoo Safari Park
On Jan. 13, 2021, the USDAﾒs (USDA) National Veterinary Services Laboratories announced confirmation of SARS-CoV-2 (the virus that…
FDA accepted for Priority Review the BLA for V114, Merckﾒs investigational 15-valent pneumococcal conjugate vaccine
On Jan. 12, 2021, Merck announced the FDA accepted for priority review a Biologics License Application (BLA) for…
Abbott announced fulfillment of Federal government purchase of 150 million BinaxNOWﾙ COVID-19 Rapid Tests
On Jan. 12, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
Global scientists doubled down on SARS-CoV-2 variants research
On Jan. 12, 2021, the WHO announced that global scientists were intensifying research into COVID-19 to expand its…
UC Berkeley scientists mapped coronavirus protein linked to disease severity
On Jan. 12, 2021, UC Berkeley HIV researchers announced that they had determined the atomic structure of a…
Regeneron announced US Government sgreement to purchase additional COVID-19 antibody cocktail doses
On Jan. 12, 2021, Regeneron announced that the U.S. Department of Health and Human Services (HHS) and the…
CureVac’s COVID-19 caccine aandidate, CVnCoV, demonstrated efficient protection of non-human primates
On Jan. 11, 2021, CureVac announced the publication of preclinical data demonstrating the induction of robust antibody and…
Abbott received CE Mark for its COVID-19 IgG quantitative antibody blood test
On Jan. 11, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
FDA conditionally approved first oral tablet to treat lymphoma in dogs
On Jan. 11, 2021, the FDA conditionally approved Anivive Lifesciences’ Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma,…
Humanigen announced CRADA agreement with US government to develop lenzilumab for COVID-19
On Jan. 10, 2021, Humanigen announced that they were partnering to make lenzilumab available to hospitalized and hypoxic…
FDA issued alert regarding SARS-CoV-2 viral mutation to health care providers and clinical laboratory staff
On Jan. 8, 2021, the FDA alerted clinical laboratory staff and health care providers that it was monitoring…
PerkinElmer announced the acquisition of Oxford Immunotec for $591 million in cash
On Jan. 7, 2021, PerkinElmer and Oxford Immunotec announce an agreement under which PerkinElmer acquired Oxford Immunotec for…
Oragenics entered into material transfer agreement with adjuvance technologies for COVID-19 vaccine adjuvant
On Jan. 7, 2021, Oragenics announced entering into a material transfer agreement with Adjuvance Technologies for use of…
Labcorp awarded CDC contract to study variants of COVID-19 virus and improve public health response
On Jan. 7, 2021, LabCorp announced that it had been awarded a contract from the Centers for Disease…
BioNTech published data on novel mRNA vaccine approach to treat autoimmune diseases in Science
On Jan. 7, 2021, BioNTech announced publication of preclinical data on its novel mRNA vaccine approach against autoimmune…
HHS announced $22 billion in funding to support expanded testing, vaccination distribution
On Jan. 6, 2021, the U.S. Department of Health and Human Services (HHS) announced the Centers for Disease…
CureVac and Bayer joined forces on COVID-19 vaccine candidate CVnCoV
On Jan. 6, 2021, Bayer announced it had signed a collaboration and services agreement with CureVac, a biopharmaceutical…
Large clinical trial tested combination monoclonal antibody therapy for mild/moderate COVID-19
On Jan. 5, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announed that a phase 2/3…
AIM ImmunoTech announced first COVID-19-induced chronic fatigue ﾓLong Haulerﾔ patient dosed with Ampligen
On Jan. 5, 2021, AIM ImmunoTech announced that the active AMP-511 Expanded Access Program (EAP) had dosed its…